Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is
the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major …

Head and neck squamous cell carcinomas (HNSCCs) are caused by tobacco and alcohol
consumption and by infection with high-risk types of human papillomavirus (HPV). Tumours …

Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …

Purpose Human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma
(OPSCC) is treatment-responsive. Definitive chemoradiation results in high cure rates but …

Purpose We tested the efficacy and toxicity of cisplatin plus accelerated fractionation with a
concomitant boost (AFX-C) versus standard fractionation (SFX) in locally advanced head …

The sinonasal cavities represent an anatomical region affected by a variety of tumours with
clinical, aetiological, pathological, and genetic features distinct from tumours at the main …

Despite advances in treatment, cancer remains the 2nd most common cause of death in the
United States. Poor cure rates may result from the ability of cancer to recur and spread after …

Objective Human papillomavirus-positive (HPV+) head and neck squamous cell carcinoma
is increasing in incidence and appears to exhibit improved response to treatment and better …

Cetuximab remains to date the only targeted therapy approved for the treatment of head and
neck squamous cell carcinoma (HNSCC). The EGFR pathway plays a key role in the …

Background Cetuximab in combination with platinum and 5-fluorouracil is the standard of
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …